A role of GABA analogues in the treatment of neurological diseases

Current Medicinal Chemistry

Volumn 17, Issue 22, 2010, Pages 2338-2347

  Gajcy, K ^a   Lochynski S ^a,b   Librowski, T ^c  

^a WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^b UNIVERSITY OF WROC AW   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Cyclopropane derivatives; GABA analogues; GABAergic receptors; Neurological diseases

Indexed keywords

3 AMINOPROPYLBUTYLPHOSPHINIC ACID; 4 AMINOBUTYRIC ACID; 4 AMINOCROTONIC ACID; BACLOFEN; BICUCULLINE; CGP 51176; CGP 56433A; GABAPENTIN; N,N' DICYCLOPENTYL 2 METHYLTHIO 5 NITRO 4,6 PYRIMIDINEDIAMINE; NIPECOTIC ACID; PEPTIDOMIMETIC AGENT; PHACLOFEN; PREGABALIN; SACLOFEN; TERPENE DERIVATIVE; TIAGABINE; UNCLASSIFIED DRUG; VIGABATRIN;

ADD ON THERAPY; ALZHEIMER DISEASE; ANXIETY DISORDER; ARTICLE; BLOOD BRAIN BARRIER; CONVULSION; DEPRESSION; DIZZINESS; DRUG ABSORPTION; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; EPILEPSY; HUMAN; HUNTINGTON CHOREA; MANIA; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; PAIN; PANIC; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHYSICAL CHEMISTRY; SEIZURE; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANIMALS; GAMMA-AMINOBUTYRIC ACID; HUMANS; NERVOUS SYSTEM DISEASES;

EID: 77955672334     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791698549     Document Type: Article

References (119)

1. Goodman, C.S.; Shatz, C.J. Developmental mechanisms that generate precise patterns of neuronal connectivity. Cell, 1993, 72, 77-98.
2. Owens, D.F.; Kriegstein, A.R. Is there more to GABA than synaptic inhibition? Nat. Rev. Neurosci., 2002, 3, 715-727.
3. Morse, D.E.; Duncan, H.; Hooker, N.; Baloun, A.; Young, G. GABA induces behavioral and developmental metamorphosis in planktonic molluscan larvae. Fed. Proc., 1980, 39, 3237-3241.
4. Kubacka, M.; Librowski, T.; Czarnecki, R.; Fra̧ckowiak, B.; Lochyński, S. Anticonvulsant and antidepressant activity of the selected terpene GABA derivatives in experimental tests in mice. Pharmacol. Rep., 2006, 58, 936-943.
5. Librowski, T.; Czarnecki, R.; Mendyk, A.; Jastrzȩbska, M. Influence of new monoterpene homologues of GABA on the central nervous system activity in mice. Pharmacol. Rep., 2000, 52, 317-321.
6. Martin, D.L.; Tobin, A.J. In GABA in the Nervous System: the View at Fifty Years; Martin, D.L.; Olsen, R.W.; Eds.; Lippincott, Williams and Wilkins, Philadelphia, 2000, pp. 25-41.
7. Bateson, A.N. Further potential of the GABA receptor in the treatment of insomnia. Sleep Med., 2006, 7S1, S3-S9.
8. Bateson, A.N. The benzodiazepine site of the GABAA receptor: an old target with new potential? Sleep Med., 2004, 5S1, S9-S15.
9. Farrant, M.; Nusser, Z. Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors. Nat. Rev. Neurosci., 2005, 6, 215-229.
10. Frølund, B.; Jensen, L,S,; Storustovu, S.I.; Stensbøl, T.B.; Ebert, B.; Kehler, J.; Krogsgaard-Larsen, P.; Liljefors, T. 4-Aryl-5-(4-Piperidyl)-3-Isoxazolol GABAA Antagonists: synthesis, pharmacology, and structure-activity relationships. J. Med. Chem., 2007, 50, 1988-1992.
11. Olsen, R.W.; Sieghart, W. GABAA receptors: Subtypes provide diversity of function and pharmacology. Neuropharmacology, 2009, 56, 141-148.
12. Barnard, E.A.; Skolnick, P.; Olsen, R.W.; Mohler, H.; Sieghart, W.; Biggio, G.; Braestrup, C.; Bateson, A.N.; Langer, S.Z. International Union of Pharmacology. XV. Subtypes of γ-aminobutyric acid receptors: classification on the basis of subunit structure and receptor function. Pharmacol. Rev., 1998, 50, 291-313.
13. Gottesmann, C. GABA mechanisms and sleep. Neuroscience, 2002, 111, 231-239.
14. Bowery, N.G.; Hill, D.R.; Hudson, A.L.; Doble, A.; Middlemiss, D.N.; Shaw, J.; Turnbull, M. (-)-Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor. Nature, 1980, 283, 92-94.
15. 3H-GABA bind to bicuculline insensitive GABAB sites in rat brain. Nature, 1981, 290, 149-152.
16. LeVine, H.: Structural features of heterotrimeric G-proteincoupled receptors and their modulatory proteins. Mol. Neurobiol., 1999, 19, 111-149.
17. Nicoll, R.A. The coupling of neurotransmitter receptors to ion channels in the brain. Science, 1988, 241, 545-551.
18. Bormann, J. Electrophysiology of GABAA and GABAB receptor subtypes. Trends Neurosci., 1988, 11, 112-116.
19. Filip, M.; Frankowska, M. GABAB receptors in drug addiction. Pharmacol. Rep., 2008, 60, 755-770.
20. Kerr, D.I., Ong, J. GABAB receptors. J. Pharmacol. Ther., 1995, 67, 187-246.
21. Drew, C.A.; Johnston, G.A.; Weatherby, R.P. Bicuculline insensitive GABA receptors: studies on the binding of (-)-baclofen to rat cerebellar membranes. Neurosci. Lett., 1984, 52, 317-321.
22. Johnston, G.A.; Curtis, D.R.; Beart, P.M.; Game, C.J.; McCulloch, R.M.; Twitclin, B. Cis-and trans-4-aminocrotonic acid as GABA analogues of restricted conformation. J. Neurochem., 1975, 24, 157-160.
23. Feigenspan, A.; Wässle, H.; Bormann, J. Pharmacology of GABA receptor Cl3 channels in rat retinol bipolar cells. Nature, 1993, 361, 159-162.
24. Quian, H.; Dowling, J.E. Selective agonists for GABAC receptors. Trends Neurosci., 1996, 19, 109-115.
25. Bormann, J.; Feigenspan, A. GABAC receptors. Trends Neurosci., 1995, 18, 515-519.
26. Boue-Grabot, E.; Taupignon, A.; Tramu, G.; Garre, M. Molecular and electrophysiological evidence for a GABAC receptor in thyrotropin- secreting cells. Endocrinology, 2000, 141, 1627-1632.
27. Ogurusu, T.; Eguchi, G.; Schingai, R. Localization of γ- aminobutyric acid (GABA) receptor ρ3 subunit in rat retina. Neuro. Report, 1997, 8, 925-927.
28. Johnston, G.A. GABAC receptors: relatively simple transmittergated ion channels? Trends Pharmacol. Sci., 1996, 17, 319-323.
29. Mehta, A.K.; Ticku, M.K. An update on GABAA receptors. Brain Res. Rev., 1999, 29, 196-217.
30. Rabow, L.E.; Russek, S.J.; Farb, D.H. From ion currents to genomic analysis - recent advances in GABAA receptor research. Synapse, 1995, 21, 189-274.
31. Chebib, M.; Johnston, G.A. GABA-activated ligand gated ion channels: medicinal chemistry and molecular biology. J. Med. Chem., 2000, 43, 1427-1446.
32. Karlsson, A.; Fonnum, F.; Malthe-Sorrensen, D.; Storm-Mathisen, J. Effect of the convulsive agent 3-mercaptopropionic acid on the levels of GABA, other amino acids and glutamate decarboxylase in different regions of the rat brain. Biochem. Pharmacol., 1974, 23, 3053-61.
33. Gale, K. GABA in epilepsy: the pharmacologic basis. Epilepsia, 1989, 30, S1-S11.
34. Dalby, N.O. Inhibition of γ-aminobutyric acid uptake: anatomy, physiology and effects against epileptic seizures. Eur. J. Pharmacol., 2003, 479, 127-137.
35. Olsen, R.W.; Avoli, M. GABA and epileptogenesis. Epilepsia, 1997, 38, 399-407.
36. Geffen, Y.; Nudelman, A.; Gil-Ad, I.; Rephaeli, A.; Huang, M.; Savitsky, K.; Klapper, L.; Winkler, I.; Meltzer, H.Y.; Weizman, A. BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. Eur. Neuropsychopharmacol., 2009, 19, 1-13.
37. Glass, M.; Dragunow, M.; Faull, R.L. the pattern of neurogeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABAA Receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience, 2000, 97, 505-519.
38. Masuda, N.; Peng, Q.; Li, Q.; Jiang, M.; Liang, Y.; Wang, X.; Zhao, M.; Wang, W.; Ross, C.A.; Duana, W. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease. Neurobiol. Dis., 2008, 30, 293-302.
39. Wu, J.Y.; Bird, E.D.; Chen, M.S.; Huang, W.M. Abnormalities of neurotransmitter enzymes in Huntington's chorea. Neurochem. Res., 1979, 4, 575-586.
40. Kleppner, S.R.; Tobin, A.J. GABA signaling: Therapeutic targets for epilepsy, Parkinson's disease and Huntington's disease. Emerging Ther. Targets, 2001, 5, 219-239.
41. Rinne, U.K.; Laaksonen, H.; Riekkinen, P.; Sonninen, V. Brain glutamic acid decarboxylase activity in Parkinson's disease. Eur. Neurol., 1974, 12, 13-19.
42. Aoyagi, T.; Wada, T.; Nagai, M.; Kojima, F.; Harada, S.; Takeuchi, T.; Takahashi, H.; Hirokawa, K.; Tsumita, T. Increased a̧-aminobutyrate aminotransferase activity in brain of patients with Alzheimer's disease. Chem. Pharm. Bull., 1990, 38, 1748-1749.
43. Davies, P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res., 1979, 171, 319-327.
44. Perry, E.K.; Gibson, P.H.; Blessed, G.; Perry, R.H.; Tomlinson, B.E. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necripsy brain tissue. J. Neurol. Sci., 1977, 34, 247-265.
45. Gunne, L.M.; Haeggstroem, J.E.; Sjoequist, B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature, 1984, 309, 347-349.
46. Mombereau, C.; Kaupmann, K.; Froestl, W.; Sansig, G.; van der Putten, H.; Cryan, J.F. Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant- like behavior. Neuropsychopharmacolog, 2004, 29, 1050-1062.
47. Partyka, A.; Klodzińska, A.; Szewczyk, B.; Wierońska, J.M.; Chojnacka-Wójcik, E.; Librowski, T.; Filipek, B.; Nowak, G.; Pilc, A. Effects of GABAB receptor ligands in rodent tests of anxietylike behavior. Pharmacol. Rep., 2007, 59, 757-762.
48. Cryan, J.F.; Kaupmann, K. Don't worry 'B' happy!: a role for GABAB receptors in anxiety and depression. Trends Pharmacol. Sci., 2005, 26, 36-43.
49. Krystal, J.H.; Sanacora, G.; Blumberg, H.; Anand, A.; Charney, D.S.; Marek, G.; Epperson, C.N.; Goddard, A.; Mason, G.F. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol. Psychiatry, 2002, 7, S71-S80.
50. Pilc, A.; Nowak, G. GABAergic hypotheses of anxiety and depression: focus on GABA-B receptors. Drugs Today (Barc), 2005, 41, 755-766.
51. 4 subunit expression and alcohol sensitivity. Alcohol, 2007, 41, 177-185.
52. Bernacki, J.; Dobrowolska, A.; Nierwińska, K.; Malecki, A. Physiology and pharmacological role of the blood-brain barrier. Pharmacol. Rep., 2008, 60, 600-622.
53. Hitchcock, S.A.; Pennington, L.D. Structure-Brain Exposure Relationships. J. Med. Chem., 2006, 49, 7559-7583.
54. Brightman, M.W.; Reese, T.S. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol., 1969, 40, 648-677.
55. O'Kane, R.L.; Martinez-Lopez, I.; DeJoseph, M.R.; Viña, J.R.; Hawkins, R.A. Na+-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. J. Biol. Chem., 1999, 274, 31891-31895.
56. Bowery, N.G.; Bonner, T.I.; Enna, S.J. International Union of Pharmacology. XXXIII. Mammalian Gamma-aminoburyric acid (B) receptors: Structure and Function. Pharmacol. Rev., 2002, 54, 247-264.
57. Yogeeswari, P.; Ragavendran, J.V.; Sriram, D. An update on GABA analogs for CNS Drug Discovery. Recent Pat. CNS Drug Discov., 2006, 1, 113-118.
58. Alstermark, C.; Amin, K.; Dinn, S.R.; Elebring, T.; Fjellstro, O.; Fitzpatrick, K.; Geiss, W.B.; Gottfries, J.; Guzzo, P.R.; Harding, J.P.; Holmén, A,; Kothare, M.; Lehmann, A.; Mattsson, J.P.; Nilsson, K.; Sundén, G.; Swanson, M.; von Unge, S.; Woo, A.M.; Wyle, M.J.; Zheng, X. Synthesis and pharmacological evaluation of novel a̧-aminobutyric acid type B (GABAB) Receptor Agonists as gastroesophageal reflux inhibitors. J. Med. Chem., 2008, 51, 4315-20.
59. Froest, W.; Mickel, S.J.; Hall, R.G.; von Sprecher, G.; Strub, D.; Baumann, P.A.; Brugger, F. Phosphinic acid analogues of GABA. New potent and selective GABAB agonists. J. Med. Chem., 1995, 38, 3297-312.
60. Jung, M.J.; Lippert, B.; Metcalf, B.W. gamma-Vinyl GABA (4- amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J. Neurochem., 1977, 29, 797-802.
61. Schechter, P.J.; Tranier, Y.; Jung, M.J. Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic gaba and gamma-vinyl GABA, two irreversible GABA-T inhibitors. Eur. J. Pharmacol., 1977, 45, 319-328.
62. Choi, S.; Silverman, R.B. Inactivation and Inhibition of a̧- Aminobutyric Acid Aminotransferase by Conformationally Restricted Vigabatrin Analogues. J. Med. Chem., 2002, 45, 4531- 4539.
63. Errante, L.D.; Williamson, A.; Spencer, D.D.; Petroff, O.A. Gabapentin and vigabatrin increase GABA in the human neocortical slice. Epilepsy Res., 2002, 49, 203-210.
64. Shields, W.D.; Sankar, R. Vigabatrin. Semin. Pediatr. Neurol., 1997, 4, 43-50.
65. Ylinen, A.; Salmenper, T.; Mumford, J.P.; Riekkinen, P.J. Longterm treatment with vigabatrin - 10 years of clinical experience. Seizure, 1999, 8, 181-183.
66. Borden, L.A. GABA transporter heterogeneity: pharmacology and cellular localization. Neurochem. Int., 1996, 29, 335-356.
67. Johnston, G.A. GABA in the nervous system: the view at fifty years. Lippincott Williams and Wilkins: Philidelphia, 2000.
68. ängehagen, M.; Ben-Menachem, E.; Rönnbäck, L.; Hansson, E. Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate. Neurochem. Res., 2003, 28, 333-340.
69. Schachter, S.C. Pharmacology and clinical experience with tiagabine. Expert Opin. Pharmacother., 2001, 2, 179-187.
70. Leppik, I.E.; Gram, L.; Deaton, R.; Sommerville, K.W. Safety of tiagabine: summary of 53 trials. Epilepsy Res., 1999, 33, 235-46.
71. Marson, A.G.; Kadir, Z.A.; Hutton, J.L.; Chadwick, D.W. The new antiepileptic drugs: A systematic review of their efficacy and tolerability. Epilepsia, 1997, 38, 859-880.
72. Dhir, A.; Akula, K.K.; Kulkarni, S.K. Tiagabine, a GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32, 835-843.
73. Bryans, J.S.; Wustrow, D.J. 3-Substituted GABA Analogs with Central Nervous System Activity: A Review. Med. Res. Rev., 1999, 19, 149-177.
74. Su, T.Z.; Lunney, E.; Campbell, G.; Oxender, D. Transport of gabapentin, a gamma-amino acid drug, by system 1 alpha-amino acid transporters: a comparative study in astrocytes, synaptosomes, and CHO cells. J. Neurochem., 1995, 64, 2125-2131.
75. Bartoszyk, G.D.; Meyerson, N.; Reimann, W.; Satzinger, G.; von Hodenberg, A. Gabapentin [pharmacology]. Curr. Prob. Epilepsy, 1986, 4, 147-163.
76. Goa, K.L.; Sorkin, E.M. Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy. Drugs, 1993, 46, 409-427.
77. Radulovic, L.L.; Taylor, C.P.; Walker, R.M. The preclinical pharmacology, pharmacokinetics and toxicology of gabapentin. Drugs Today, 1995, 31, 597-611.
78. Vasudev, P.G.; Chatterjee, S.; Shamala, N.; Balaram, P. Gabapentin: A stereochemically constrained a̧-amino acid residue in hybrid peptide design. Acc. Chem. Res., 2009, 42, 1628-1639.
79. Zaremba, P.D.; Bialek, M.; Blaszczyk, B.; Cioczek, P.; Czuczwar, S.J. Non-epilepsy uses of antiepileptic drugs. Pharmacol. Rep., 2006, 58, 1-12.
80. Andruszkiewicz, R.; Silverman, R.B. A convenient synthesis of 3- alkyl-4-aminobutanoic acids. Synthesis, 1989, 12, 953-955.
81. Silverman, R.B.; Andruszkiewicz, R.; Nanavanti, S.M.; Taylor, C.P.; Vartanian, M.G. 3-alkyl-4-aminobutyric acids: the first class of anticonvulsant agents that activates l-glutamic acid decarboxylase. J. Med. Chem., 1991, 34, 2295-2298.
82. Taylor, C.P.; Vartanian, M.G.; Andruszkiewieicz, R.; Silverman, R.B. 3-alkyl GABA and 3-alkylglutamic acid analogues: two new classes of anticonvulsant agents. Epilepsy Res., 1992, 11, 103-110.
83. Taylor, C.P.; Vartanian, M.G.; Yuen, P.W.; Bigge, C.; Suman- Chauhan, N.; Hill, D.R. Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res., 1993, 14, 11-15.
84. Taylor, C.P.; Vartanian, M.G. Profile of anticonvulsant activity of CI-1008 (Pregabalin) in animal models. Epilepsia, 1997, 38, 35.
85. Williamson, J.; Lothman, C.T.; Bertram, E. Comparison of S-(1)-3 Isobutyl GABA and Gabapentin against kindled hippocampal seizures. Epilepsia, 1997, 38, 29.
86. Dworkin, R.H.; Kirkpatrick, P. Pregabalin. Nat. Rev. Drug Discovery, 2005, 4, 455-456.
87. Zareba, G. Pregabalin: A new agent for the treatment of neuropathic pain. Drugs Today, 2005, 41, 509-516.
88. Guay, D.R. Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? Am. J. Geriatr. Pharmacother., 2005, 3, 274-287.
89. Sills, G.J. The mechanism of action of gabapentin and Pregabalin. Curr. Opin. Pharmacol., 2006, 6, 108-113.
90. 2-δ Ligands for the Treatment of Neuropathic Pain. J. Med. Chem., 2007, 50, 2569-2575.
91. Su, T.Z.; Feng, M.R.; Weber, M.L. Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells. J. Pharmacol. Exp. Ther., 2005, 313, 1406-1415.
92. Feng, M.R.; Turluck, D.; Burleigh, J.; Lister, R.; Fan, C.; Middlebrook, A.; Taylor, C.; Su, T.Z. Brain microdialysis and PK/PD correlation of pregabalin in rats. Eur. J. Drug Metab. Pharmacokinet., 2001, 26, 123-128.
93. Baillie, J.K.; Power, I. The mechanism of action of gabapentin in neuropathic pain. Curr. Opin. Invest. Drugs, 2006, 7, 33-39.
94. 2-δ subunit of a calcium channel. J. Biol. Chem., 1996, 271, 5768-5776.
95. 2-δ ligands: Voltage sensitive calcium channel (VSCC) modulators. J. Clin. Psychiatr., 2004, 65, 1033-1034.
96. 2-δ Protein. J. Med. Chem., 2005, 48, 2294-2307.
97. Cheng, J.K.; Chiou, L.C. Mechanisms of the antinociceptive action of gabapentin. J. Pharmacol. Sci., 2006, 100, 471-486.
98. 2-δ ligands: novel modulators of neurotransmitter release. Trends Pharmacol. Sci., 2007, 28, 75-82.
99. Guery, S.; Floersheim, P.; Kaupmann, K.; Froestl, W. Syntheses and optimization of new GS39783 analogues as positive allosteric modulators of GABA B receptors. Bioorg. Med. Chem. Lett., 2007, 17, 6206-6211.
100. Chaki, S.; Okubo, T.; Sekiguchi, Y. Non-monoamine-based approach for the treatment of depression and anxiety disorders. Recent Pat. CNS Drug Discov., 2006, 1, 1-27.
101. Nakagawa, Y.; Sasaki, A.; Takashima, T. The GABA(B) receptor antagonist CGP36742 improves learned helplessness in rats. Eur. J. Pharmacol., 1999, 381, 1-7.
102. Nowak, G.; Partyka, A.; Paȩucha, A.; Szewczyk, B.; Wieroγska, J.M.; Dybaȩa, M.; Metz, M.; Librowski, T.; Froestl, W.; Papp, M.; Pilc, A. Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. Br. J. Pharmacol., 2006, 149, 581-590.
103. 2-δ Protein J. Med. Chem., 2005, 48, 3026-3035.
104. Allan, R.D.; Curtis, D.R.; Headley, P.M.; Johnston, G.A.; Lodge, D.; Twitchin, B. The synthesis and activity of cis- and trans-2-(aminomethyl)cyclopropanecarboxylic acid as conformationally restricted analogues of GABA. J. Neurochem., 1980, 34, 652-654.
105. Spivak, C.E., Whiting, P.; Dawson, V.L.; Schaeffer, J.C.; Uhl, G.R. Pharmacology of GABA ρ1 and GABA α/β receptors expressed in Xenopus oocytes and COS cells. Br. J. Pharmacol., 1993, 109, 200-206.
106. Kusama, T.; Wang, T.L.; Guggino, W.B.; Cutting, G.R.; Uhl, G.R. GABA ń2 receptor pharmacology profile: GABA recognition site similarities to ń1. Eur. J. Pharmacol., 1993, 245, 83-84.
107. Duke, R.K.; Chebib, M.; Hibbs, D.E.; Mewett, K.N.; Johnston, G.A. Synthesis and resolution of 2-methyl analogues of GABA. Tetrahedron: Asymmetry, 2004, 15, 1745-1751.
108. Borowicz, K.K.; Zadroρniak, M.; Czuczwar, S.J. Trans-4-aminocrotonic acid (TACA), a potent agonist of GABAA and GABAC receptors, shows a proconvulsant action in the electroconvulsive threshold test in mice. Pharmacol. Rep., 2005, 57, 121-123.
109. Krehan, D.; Frolund, B.; Krogsgaard-Larsen P.; Kehler, J.; Johnston, G.A.; Chebib, M. Phosphinic, phosphonic and seleninic acids bioisosters of isonipecotic acids as novel and selective GABAC receptor antagonists. Neurochem. International, 2003, 42, 561-565.
110. Duke, R.K.; Chebib, M.; Balcar, V.J.; Allan, R.D.; Mewett, K.N.; Johnston, G.A. (+)- and (-)-cis-2-aminomethylcyclopropanecarboxylic acids show opposite pharmacology at recombinant rho(1) and rho(2) GABA(C) receptors. J. Neurochem., 2000, 75, 2602-2610.
111. Lochyγski, S.; Kuȩdo, J.; Frńckowiak, B.; Holband, J.; Wójcik, G. Stereochemistry of terpene derivatives. Part 2: Synthesis of new chiral amino acids with potential neuroactivity. Tetrahedron: Asymmetry, 2000, 11, 1295-1298.
112. Lochyγski, S.; Frńckowiak, B.; Gajcy, K.; Kusiak, A.; Librowski, T.; Kubacka, M. Polish Patent, Application P-382189, 2007.
113. Gajcy, K.; Librowski, T.; Lochyγski, S. Concise Synthesis of Nonprotein Amino Acid from Natural Product via Schmidt Reaction. Lett. Org. Chem., 2009, 6, 186-188.
114. Burgess, K.; Ho, K.K. γ-Turn Structure Induced by (2S,3S)-2,3-Methanomethonine. J. Am. Chem. Soc., 1994, 116, 799-800.
115. Burgess, K.; Ho, K.K. Asymmetric Syntheses of All Four Stereoisomers of 2,3-Methanomethionine. J. Org. Chem., 1992, 57, 5931-5936.
116. Burgess, K.; Li, W. Practical Asymmetric Syntheses of All Four 2,3-Methanoleucine Stereoisomers. Tetrahedron Lett., 1995, 16, 2725-2728.
117. Hübner, J.; Liebscher, J.; Pätzel, M. Optically active nitroalkenes - synthesis, addition reactions and transformation into amino acids. Tetrahedron, 2002, 58, 10485-10500.
118. Wipf, P.; Stephenson, C.R. Three-Component Synthesis of α,β- Cyclopropyl-γ-Amino Acids. Org. Lett., 2005, 7, 1137-1140.
119. Wipf, P.; Werner, S.; Woo, G.H.; Stephenson, C.R.; Walczak, M.A.; Coleman, C.M.; Twining, L.A. Application of divergent multi-component reactions in the synthesis of a library of peptidomimetics based on γ-amino-α,β-cyclopropyl acids. Tetrahedron, 2005, 61, 11488-11500.